Ruiz-Babot Gerard, Hadjidemetriou Irene, King Peter James, Guasti Leonardo
Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London , London , UK.
Front Endocrinol (Lausanne). 2015 May 6;6:70. doi: 10.3389/fendo.2015.00070. eCollection 2015.
Adrenal disease, whether primary, caused by defects in the hypothalamic-pituitary-adrenal (HPA) axis, or secondary, caused by defects outside the HPA axis, usually results in adrenal insufficiency, which requires lifelong daily replacement of corticosteroids. However, this kind of therapy is far from ideal as physiological demand for steroids varies considerably throughout the day and increases during periods of stress. The development of alternative curative strategies is therefore needed. In this review, we describe the latest technologies aimed at either isolating or generating de novo cells that could be used for novel, regenerative medicine application in the adrenocortical field.
肾上腺疾病，无论是原发性的（由下丘脑 - 垂体 - 肾上腺（HPA）轴缺陷引起）还是继发性的（由HPA轴以外的缺陷引起），通常都会导致肾上腺功能不全，这需要终身每日补充皮质类固醇。然而，这种治疗方法远非理想，因为类固醇的生理需求在一天中变化很大，并且在压力期间会增加。因此，需要开发替代的治疗策略。在这篇综述中，我们描述了旨在分离或从头生成可用于肾上腺皮质领域新型再生医学应用的细胞的最新技术。
